Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Wermelskirchen

2 clinical trials in Wermelskirchen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Wermelskirchen at a glance
2
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 trials in Wermelskirchen

Open in trial search

Gastrooesophageal cancer+1

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:FRUQUINTINIB
  • Sponsor:Fondation Franc.Cancerologie Digestive

Colorectal cancer metastatic

Not yet recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Other cities in Germany

The busiest research cities in the country

All 515 cities in Germany

Clinical research in Wermelskirchen

What the registry says about research in the country

01 Wermelskirchen
Neoplasms – Metastatic Colorectal Cancer
In Wermelskirchen, researchers are exploring new treatment strategies for metastatic colorectal cancer within the broader field of Neoplasms. The current study evaluates the impact of scheduled treatment breaks versus continuous therapy to improve time to failure and overall disease management. FOLFIRI plus cetuximab regimen Treatment break strategy RAS/BRAF wild-type patient subgroup First‑line therapy optimization This work aims to refine first‑line options and could lead to more personalized schedules for patients in the region.
Neoplasms – Metastatic Oeso‑Gastric Adenocarcinoma
A separate trial in the city targets metastatic oeso‑gastric adenocarcinoma, assessing whether adding fruquintinib to standard trifluridine/tipiracil therapy extends overall survival. The research builds on the Neoplasms therapeutic area and seeks to expand effective options for advanced gastrointestinal cancers. Trifluridine/tipiracil backbone Fruquintinib angiogenesis inhibitor Overall survival comparison Randomized phase III design Results could offer a new combination approach for patients with limited treatment alternatives, improving outcomes in this challenging disease.
Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.